Corvus Pharmaceuticals (CRVS) Director Granted 30,000 Options at $7.04

Corvus Pharmaceuticals, Inc. (CRVS) reported an insider equity transaction by Director David Scott Moore on 10/02/2025.

Accepted by SEC EDGAR 10/06/2025 - 04:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. (CRVS) reported an insider equity transaction by Director David Scott Moore on 10/02/2025. The filing discloses an award of 30,000 stock options with an exercise price of $7.04. The options vest in three equal annual installments (one-third each year) beginning on 10/02/2025 and expire on 10/02/2035 subject to the reporting person’s continued service. The Form 4 was signed on 10/06/2025 by an attorney-in-fact on behalf of the reporting person.

Positive

• Director equity award: 30,000 options align a board member’s interests with shareholders
• Multi-year vesting: vesting over three years supports retention through 10/02/2027

Negative

• Potential dilution: exercise of 30,000 options would increase share count if exercised
• Exercise price locked: options priced at $7.04 may have limited upside if market remains below that level

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Moore David Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from October 2, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Corvus Pharmaceuticals (CRVS) report on the Form 4?

Director David Scott Moore was granted 30,000 stock options with an exercise price of $7.04 on 10/02/2025.

When do the options granted to David Scott Moore vest?

The options vest in three equal annual installments, with one-third vesting on each anniversary beginning 10/02/2025.

What is the expiration date of the options reported for CRVS?

The options expire on 10/02/2035.

Who filed the Form 4 for David Scott Moore?

The Form 4 was signed by Leiv Lea, as Attorney-in-Fact for David Scott Moore on 10/06/2025.

How many shares would be underlying the reported derivative award?

The reported stock option covers 30,000 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moore David Scott

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.04	10/02/2025		A		30,000		(1)	10/02/2035	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from October 2, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

	/s/ Leiv Lea, as Attorney-in-Fact for David Scott Moore	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.